Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia

Haematologica

Volumn 96, Issue 3, 2011, Pages 384-392

  Hollink, Iris H I M ^a   van den Heuvel Eibrink, Marry M ^a   Arentsen Peters, Susan T C J M ^a   Zimmermann, Martin ^b   Peeters, Justine K ^c   Valk, Peter J M ^c   Balgobind, Brian V ^a   Sonneveld, Edwin ^d   Kaspers, Gertjan J L ^d,e   de Bont, Eveline S J M ^f   Trka, Jan ^g   Baruchel, Andre ^h   Creutzig, Ursula ⁱ   Pieters, Rob ^a   Reinhardt, Dirk ^b   Zwaan, C Michel ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Dutch Childhood Oncology Group DCOG   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF GRONINGEN   (Netherlands)

^g CHARLES UNIVERSITY   (Czech Republic)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

CEBPA mutation; Molecular marker; Pediatric acute myeloid leukemia; Prognostic significance; Promoter hypermethylation

Indexed keywords

ANTHRACYCLINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; CEBPA GENE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MUTANT; PRESCHOOL CHILD; PROGNOSIS; PROMOTER REGION; PROTEIN FUNCTION; SCHOOL CHILD; STEM CELL TRANSPLANTATION; WILD TYPE;

ADOLESCENT; ADULT; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CHILD; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK ASSESSMENT; SURVIVAL RATE;

EID: 79952323651     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.031336     Document Type: Article

References (43)

1. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica. 2007; 92(11):1519-32.
2. Hollink IH, van den Heuvel-Eibrink M. M, Zimmermann M, Balgobind BV, Arentsen-Peters ST, Alders M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood. 2009;113(23):5951-60.
3. Hollink IH, Zwaan CM, Zimmermann M, Arentsen-Peters TC, Pieters R, Cloos J, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia. 2009;23(2):62-70.
4. Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood. 2003;102(7): 2387-94.
5. Frohling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22(4): 624-33.
6. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-18.
7. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA. 1997;94(2):569-74.
8. Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity. 2004;21(6):853-63.
9. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein- alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001;27(3):263-70.
10. Helbling D, Mueller BU, Timchenko NA, Schardt J, Eyer M, Betts DR, et al. CBFBSMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood. 2005;106 (4):1369-75.
11. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med. 2001;7(4):444-51.
12. Radomska HS, Basseres DS, Zheng R, Zhang P, Dayaram T, Yamamoto Y, et al. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med. 2006;203(2):371-81.
13. Cilloni D, Carturan S, Gottardi E, Messa F, Messa E, Fava M, et al. Down-modulation of the C/EBPalpha transcription factor in core binding factor acute myeloid leukemias. Blood. 2003;102(7):2705-6.
14. Chim CS, Wong AS, Kwong YL. Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia. Br J Haematol. 2002;119(4):988-90.
15. Wouters BJ, Jorda MA, Keeshan K, Louwers I, Erpelinck-Verschueren CA, Tielemans D, et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood. 2007;110(10):3706-14.
16. Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C. CEBPA point mutations in hematological malignancies. Leukemia. 2005;19(3):329-34.
17. Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer. 2004;4(5):394-400.
18. Pabst T, Mueller BU. Transcriptional dysregulation during myeloid transformation in AML. Oncogene. 2007;26(47):6829-37.
19. Asou H, Gombart AF, Takeuchi S, Tanaka H, Tanioka M, Matsui H, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer. 2003;36(2):167-74.
20. Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res. 2005;11(4):1372-9.
21. Barjesteh van Waalwijk van Doorn Khosrovani S, Erpelinck C, Meijer J, van Oosterhoud S, van Putten WL, Valk PJ, et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J. 2003;4(1):31-40.
22. Gombart AF, Hofmann WK, Kawano S, Takeuchi S, Krug U, Kwok SH, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood. 2002;99(4):1332-40.
23. Snaddon J, Smith ML, Neat M, Cambal- Parrales M, Dixon-McIver A, Arch R, et al. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer. 2003;37(1):72-8.
24. Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100(8):2717-23.
25. Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2009; 113(26):6558-66.
26. Liang DC, Shih LY, Huang CF, Hung IJ, Yang CP, Liu HC, et al. CEBPalpha mutations in childhood acute myeloid leukemia. Leukemia. 2005;19(3):410-4.
27. Wouters BJ, Lowenberg B, Erpelinck- Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009 Mar 26;113(13):3088-91.
28. Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010;28(4):570-7.
29. Kaspers GJ, Veerman AJ, Pieters R, Broekema GJ, Huismans DR, Kazemier KM, et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer. 1994;70(6):1047-52.
30. Van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, Buijs-Gladdines J, et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood. 2006;108(10): 3520-9.
31. Zuurbier L, Homminga I, Calvert V, Winkel MT, Buijs-Gladdines JG, Kooi C, et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia. 2010;24(12):2014-22.
32. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn Khosrovani S, Boer JM, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350 (16):1617-28.
33. Wouters BJ, Louwers I, Valk PJ, Lowenberg B, Delwel R. A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profilingbased clustering of AML. Blood. 2007;109 (1):389-90.
34. Keeshan K, He Y, Wouters BJ, Shestova O, Xu L, Sai H, et al. Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell. 2006;10(5): 401-11.
35. Salmond RJ, Filby A, Qureshi I, Caserta S, Zamoyska R. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol Rev. 2009;228(1):9-22.
36. Kirstetter P, Schuster MB, Bereshchenko O, Moore S, Dvinge H, Kurz E, et al. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell. 2008;13(4):299-310.
37. Bereshchenko O, Mancini E, Moore S, Bilbao D, Månsson R, Luc S, et al. Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. Cancer Cell. 2009;16(5):390-400.
38. Somervaille TC, Cleary ML. Preview. Mutant CEBPA: priming stem cells for myeloid leukemogenesis. Cell Stem Cell. 2009;5(5):453-4.
39. Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004;351(23):2403-7.
40. Renneville A, Mialou V, Philippe N, Kagialis-Girard S, Biggio V, Zabot MT, et al. Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia. 2009;23(4):804-6.
41. Corbacioglu A, Frohling S, Mendla C, Eiwen K, Habdank M, Dohner H. Germline mutation screening in cytogenetically normal acute myeloid leukemia with somatically acquired CEBPA mutations. Blood. 2007;110:114a (abstract 363).
42. Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen SS, et al. Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res. 2008;68(9):3142-51.
43. Figueroa ME, Wouters BJ, Skrabanek L, Glass J, Li Y, Erpelinck-Verschueren CA, et al. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood. 2009;113(12):2795-804.